SSAO INHIBITORS AND USE THEREOF
The application relates to a compound of Formula (I′) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I′) or (I), and a method of treating or preventing a disease in which SSAO plays a role.
1 .- 75 . (canceled)
76 . A compound selected from the group consisting of:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.
77 . A pharmaceutical composition comprising the compound of claim 76 , or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable diluent, excipient, or carrier.
78 . The compound of claim 76 , which is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.
79 . The compound of claim 78 , which is:
80 . The compound of claim 78 , which is a pharmaceutically acceptable salt of:
81 . The compound of claim 76 , which is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.
82 . The compound of claim 81 , which is:
83 . The compound of claim 81 , which is a pharmaceutically acceptable salt of:
84 . The compound of claim 76 , which is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.
85 . The compound of claim 84 , which is:
86 . The compound of claim 84 , which is a pharmaceutically acceptable salt of:
87 . The compound of claim 76 , which is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.
88 . The compound of claim 87 , which is:
89 . The compound of claim 87 , which is a pharmaceutically acceptable salt of:
90 . The compound of claim 76 , which is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.
91 . The compound of claim 90 , which is:
92 . The compound of claim 90 , which is a pharmaceutically acceptable salt of:
93 . The compound of claim 76 , which is:
or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof.
94 . The compound of claim 93 , which is:
95 . The compound of claim 93 , which is a pharmaceutically acceptable salt of:
96 . A method of modulating SSAO or treating a SSAO-mediated disorder, comprising administering to a subject in need thereof, a therapeutically effective amount of the compound of claim 76 , or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein the SSAO-mediated disorder is liver inflammation, liver fibrosis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, or stroke.